AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03846765
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylephrine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Phenylephrine will be started at 0,2 μg/kg/min and adjusted according to the patient's hemodynamic status. The dose will be adjusted to MAP during a 30-minute study period.
Trial: NCT01996852
Drug: sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg of sildenafil citrate will be given twice a week to interested patients. Participants may start Sildenafil at a lower dose when needed.~To increase external validity, participants will be given the choice of using Sildenafil in the study.
Trial: NCT03086395
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be treated with a total of 2 cycles of obinutuzumab. Cycle 1 obinutuzumab dose is 1000 mg given intravenously (IV) on day 1, 8, 15. Cycle #1 day #1 dose of 1000 mg of obinutuzumab will be administered over 2 days. During Cycle 1, Day 1, 100 mg will be administered. On the following day (Cycle 1, Day 2), 900 mg will be administered. During cycle 2 patients will receive a single dose of obinutuzumab1000 mg IV on day 1. Cycle #2 will be given 21 days after the first cycle.
Trial: NCT00868348
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 ml infiltration 4 ml intraarticular bolus injection of placebo
Trial: NCT00857389
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 40 mg/m\^2 through a central venous catheter (CVC) over 1 hour daily on 4 consecutive days (Days -6 through -3).
Trial: NCT00857389
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Test dose of 0.5 mg/kg through a central venous catheter (CVC)over 30 minutes on Day -7.~High dose 5,000 µMol-min through a central venous catheter (CVC) over 3 hours on Days -5, -4, and -3.
Trial: NCT00857389
Drug: Thymoglobulin (ATG)
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg/kg by vein on Day -4 and 1.75 mg/kg on Day -3.
Trial: NCT00857389
Drug: G-CSF (Filgrastim)
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 µg/kg Injection under the skin once a day, starting 1 week after transplant, until blood cell levels return to normal.
Trial: NCT00857389
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered as indicated after transplant day 90, if no GVHD is present. Tacrolimus is adjusted trough level of 5-15 ng/mL.
Trial: NCT03846765
Drug: Dobutamine
RxNorm normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dobutamine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Dobutamine will be started at 2 μg/kg/min; and adjusted according to the patient's hemodynamic status .The dose will be adjusted to MAP during a 30-minute study period.
Trial: NCT04066023
Drug: C213 Microneedle System
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The C213 System is a proprietary disposable patch and a reusable applicator. The zolmitriptan-coated titanium microneedle array (3 cm\^2 array) is attached to a 5 cm\^2 adhesive patch.
Trial: NCT04458857
Drug: Fremanezumab
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose A or Dose B subcutaneous
Trial: NCT03097107
Drug: Saroglitazar Magnesium 1 mg
RxNorm normalized name: pitavastatin magnesium 1 MG
DrugBank: Saroglitazar (DB13115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomly assigned patients will receive saroglitazar magnesium 1 mg orally once each morning before breakfast for 12 weeks
Trial: NCT03097107
Drug: Saroglitazar Magnesium 2 mg
RxNorm normalized name: pitavastatin magnesium 2 MG
DrugBank: Saroglitazar (DB13115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomly assigned patients will receive saroglitazar magnesium 2 mg orally once each morning before breakfast for 12 weeks
Trial: NCT03097107
Drug: Saroglitazar Magnesium 4 mg
RxNorm normalized name: pitavastatin magnesium 4 MG
DrugBank: Saroglitazar (DB13115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomly assigned patients will receive saroglitazar magnesium 4 mg orally once each morning before breakfast for 12 weeks
Trial: NCT02197260
Drug: 3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic antibiotics after sub gingival mechanical debridement
Trial: NCT03018834
Drug: ANAKINRA 100 mg/daily subcutaneously
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
Trial: NCT04107675
Drug: Liposomal Cyclosporine A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal Cyclosporine A is administered at different dosages in the first two arms (10 mg bid and 5 mg bid, respectively) with a new technology of nebulizing liquid drugs, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
Trial: NCT01552694
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral, 100 mg/day for 2 months
Trial: NCT03700411
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine intravenous
Trial: NCT03700411
Drug: Piritramid
RxNorm normalized name: Piritramida
DrugBank: Piritramide (DB12492)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piritramid intravenous
Trial: NCT00749645
Drug: FANG(30)
RxNorm normalized name: FANG
DrugBank: Gemogenovatucel-T (DB17412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andrographolide formula Oral tablets, 30mg, three times per day, during a total of 105 continuous days.
Trial: NCT01965522
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D 2000 IU taken orally once daily. This is in the form of one capsule which contains two pills of vitamin D, 1000 IU each.
Trial: NCT00735904
Drug: AG-013736
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-013736 5 mg tablets orally, twice daily, until disease progression
Trial: NCT00735904
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200-mg or 1 g lyophilized powder, to be administered as 1250 mg/m\^2 IV infusion on Day 1 and Day 8 of 21-day cycle. For a maximum of 6 cycles
Trial: NCT00502047
Drug: Plantago ovata husk
RxNorm normalized name: Plantago ovata seed
DrugBank: Plantago ovata seed (DB14585)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01766128
Drug: Zonisamide
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The first arm will be treated by zonisamide
Trial: NCT00396201
Drug: G-CSF Plus Plerixafor
RxNorm normalized name: G-CSF
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomized participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
Trial: NCT02500186
Drug: Luseogliflozin
RxNorm normalized name: luseogliflozin
DrugBank: Luseogliflozin (DB12214)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Study patients orally receive luseogliflozin 2.5 mg s.i.d. before breakfast for 7 days from the 8th day of starting the study meal to the 14th day.
Trial: NCT03137615
Drug: local anaesthetic injection
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The surgeon infiltrates the nasal septum with local anaesthesia as per usual practice. This consists of Moffet's solution and lidocaine with adrenaline (1:200,000).
Trial: NCT01790503
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00145405
Drug: Lanreotide Autogel and Octreotide LAR
RxNorm normalized name: octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01766960
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Five milligrams of intravenous morphine will be administered.
Trial: NCT00413647
Drug: CardioPET
RxNorm normalized name: Cardiopet
DrugBank: Cardiopet (DB18913)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01810653
Drug: Macrogol (Transipeg, BAY81-8430)
DrugBank: Polyethylene glycol (DB09287)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Up to 4 sachets per day based on individual titration
Trial: NCT01810653
Drug: Macrogol (Forlax)
DrugBank: Polyethylene glycol (DB09287)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Up to 4 sachets per day based on individual titration
Trial: NCT00857389
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post haploidentical stem cell transplant participants: 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses.
Trial: NCT00683163
Drug: PTH(1-84)
RxNorm normalized name: PTH(1-84)
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4 mg injected subcutaneously (in the abdomen) daily
Trial: NCT00735904
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg/ml solution or as lyophilized powder, to be administered as 80 mg/m\^2 IV infusion on Day 1 of 21-day cycle. For a maximum of 6 cycles
Trial: NCT00359905
Drug: Silodosin
RxNorm normalized name: Silodosin
DrugBank: Silodosin (DB06207)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 8 mg daily for 12 weeks
Trial: NCT00359905
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4 mg daily for 12 weeks
Trial: NCT00003332
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003332
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03204539
Drug: Wilate
RxNorm normalized name: Wilate
DrugBank: Von Willebrand factor human (DB13133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wilate® is a high-purity (i.e. 100 IU FVIII/mg total protein) pdVWF/FVIII complex concentrate.Wilate® possesses all the important features asked for in ITI, namely high purity, a very high pathogen safety profile, and an excellent protection of its FVIII by VWF - all achieved through unique, novel, and innovative techniques.
Trial: NCT01027611
Drug: proparacaine HCL 0.5% + 4% lidocaine solution
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01027611
Drug: 3.5% viscous lidocaine gel
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01235559
Drug: bitopertin [RO4917838] level 1
DrugBank: Bitopertin (DB12426)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose level 1, once a day for 52 weeks
Trial: NCT01235559
Drug: bitopertin [RO4917838] level 2
DrugBank: Bitopertin (DB12426)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose level 2, once a day for 52 weeks
Trial: NCT00634634
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sorafenib dose will be given at a daily dose to be determined based upon the phase of study that patient is enrolled The phase II dose of sorafenib will be determined from the phase I portion of the study.
Trial: NCT00634634
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take letrozole orally at a daily dose of 2.5 mg/day on Days 1 through 28
Trial: NCT04504526
Drug: 68Ga-Pentixafor
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dose of 74-148 MBq (2-4 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions by PET/CT.
Trial: NCT02640183
Drug: EMLA
RxNorm normalized name: EMLA
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00885703
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Step 1: \[For participants randomized to Fluconazole\] Induction dose of daily treatment of fluconazole given orally (adjusted according to weight).~Step 2: \[For participants randomized to Ampho B only\] If participant is intolerant to Ampho B, participant transitions to fluconazole dosage of 400-800mg daily given orally.~Step 3: If participant has a negative culture before week 10, participant transitions to consolidation therapy at dosage of 400mg daily given orally.~Step 4: At week 10, participant transitions to maintenance therapy at dosage of 200mg daily given orally.
Trial: NCT00885703
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Step 1: \[For participants randomized to Ampho B\] Ampho B given intravenously for approximately 2 weeks at a dosage of 0.7 to 1.0 mg/kg, dependent on a participant's weight
Trial: NCT00675922
Drug: Sulfamylon 5% and Silver Nitrate Soaks
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of Sulfamylon and Silver Nitrate Solution to burn wound daily
Trial: NCT00075400
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT03226522
Drug: AXS-05
RxNorm normalized name: AX
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AXS-05
Trial: NCT03226522
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion
Trial: NCT03343795
Drug: oral progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: daily
Trial: NCT03343795
Drug: intramuscular progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: every week
Trial: NCT01576042
Drug: amiodarone
RxNorm normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
Trial: NCT01576042
Drug: sotalol
RxNorm normalized name: Sotalol
DrugBank: Sotalol (DB00489)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The choice and dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
Trial: NCT00635037
Drug: bupivacaine and acupuncture
RxNorm normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.~* acupuncture twice a week
Trial: NCT00645814
Drug: placebo for adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg at Week 0 and 40 mg eow through Week 11
Trial: NCT00645814
Drug: adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg at Week 0 and 40 mg eow through Week 11
Trial: NCT00645814
Drug: adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg at Week 0 and 40 mg weekly through Week 11
Trial: NCT02712476
Drug: mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This drug is in our routine use of neuroanesthesia, are given in peroperatifyl brain relaxation
Trial: NCT02712476
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This drug is can be used alone or with mannitol for brain relaxation
Trial: NCT00807196
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 250mg/m2 day -21 and day -14 of preparative regimen
Trial: NCT00807196
Drug: 90Y ibritumomab tiuxetan (Zevalin)
RxNorm normalized name: ibritumomab tiuxetan (90Y)
DrugBank: Ibritumomab tiuxetan (DB00078)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.4 mCi/kg IV on day -14 of preparative regimen
Trial: NCT00807196
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
Trial: NCT02433977
Drug: Sodium Nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)
Trial: NCT02433977
Drug: Sodium Nitrate
RxNorm normalized name: Sodium Nitrate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)
Trial: NCT03154645
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a diuretic
Trial: NCT00651820
Drug: Collagenase Santyl
RxNorm normalized name: collagenase Topical Ointment [Santyl]
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermatome-induced skin wounds treated with drug active.~Each subject serves as his own control receiving both treatments in parallel.
Trial: NCT02433639
Drug: TH-302 monotherapy
RxNorm normalized name: TH-9402 free base
DrugBank: TH-9402 free base (DB17148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TH-302 (480 ) mg/m2 D1, D8, D15 Q 4 weeks
Trial: NCT03947489
Drug: Sarpogrelate HCL 300mg
RxNorm normalized name: amiodarone hydrochloride 300 MG
DrugBank: Sarpogrelate (DB12163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single oral dose administration in healthy volunteers under fasting condition
Trial: NCT00584025
Drug: levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 - 500mg IV q 15 min
Trial: NCT01854047
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution for injection, Subcutaneous injection
Trial: NCT01854047
Drug: Salbutamol/albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inhalation as needed
Trial: NCT01854047
Drug: Levosalbutamol/levalbuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inhalation as needed
Trial: NCT04456296
Drug: Fortesta
RxNorm normalized name: Fortesta
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
Trial: NCT04456296
Drug: Testim
RxNorm normalized name: Testim
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
Trial: NCT03134222
Drug: Lanraplenib
RxNorm normalized name: Lanraplenib
DrugBank: Lanraplenib (DB14770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg tablets administered orally once daily with or without food